Save Second Base, The Innovators: Raadysan BioTech

Triple-Negative Breast Cancer makes up about 10-20% of breast cancer diagnoses and is more aggressive than other breast cancer types. Which means it has a worse prognosis. It’s also more common among younger women, black and Hispanic women, and those with the BRCA1 mutation.

Battling Triple Negative Breast Cancer is difficult because there are no targeted therapies currently available for its treatment, leaving a gaping void that needs to be addressed with utmost urgency.

Luckily, there are talented scientists working to change that.

But first – what is Triple-negative breast cancer?

It is a kind of breast cancer that does not have any of the receptors that are commonly found in breast cancer. Think of cancer cells as a baseball diamond with runners on. There are three bases, called receptors:

  • One is for the female hormone estrogen.
  • One is for the female hormone progesterone.
  • One is a protein called human epidermal growth factor.

If your cancer is heading to any of these three bases, doctors have a few options (like hormone therapy or other drugs) to tag out the cancer and help destroy the cancer cells.

But if you have triple-negative breast cancer, it means those three bases aren’t loaded. So doctors have fewer “plays to make” for treatment.

So what can be done?

Meet Rakhee Gupte, MS, Ph.D., President & CEO of Raadysan Biotech, Inc., a biotechnology company involved in the Research & Development of highly differentiated therapies for Triple Negative Breast Cancer.

Dr. Gupte has over 20 years of academic (microbiology, biochemistry, molecular, and cell biology & immunology) and pharmaceutical experience. She has identified several novel signaling pathways in oncology and cardiovascular diseases that led to the discoveries of unique molecular targets for therapeutic intervention. She holds 5 US patents and has published over 20 abstracts and 18 full-length publications in peer-reviewed scientific journals.

 As part of our “Save Second Base” series on breast cancer, we were thrilled to speak with Dr. Gupte about her company’s drug leads.

Raadysan’s drug leads offer the following benefits:

  • It’s the first targeted therapy for Triple Negative Breast Cancer.
  • It directly targets DNA replication/cell proliferation machinery.
  • It will not directly damage the DNA, as observed with other conventional anti-cancer drugs, thus minimizing cell toxicity, and improving patient survival rates.
  • It is receptor-independent and hence will be an effective therapy for all types of breast cancer.
  • It inhibits cancer cell viability by 95%.
  • It causes cancer cell death.
  • It selectively targets only cancer cells.

You can check out the full interview below!

2 Comments

  1. Debra Ebeley

    Hello, I found your video about the treatment for triple negative breast cancer that you have developed and I wanted to contact you about the possibility of becoming involved in your clinical trial as soon as possible. I am dealing with the spread of triple negative breast cancer after five years. I am 60 years old and have fought so hard to survive to this point. I have 11 parrots at home, one of whom has been with me for 35 years. My birds need me and I need them. I have been through terrible trauma and stress and struggle in the last few years since my diagnosis and I have hung on in the hope of a treatment or cure that would finally end this nightmare for me. Can you please help me? I live in Pennsylvania in the United States and will find a way to travel to you if you accept me into your trial. I want so desperately to live. Please, help me ! Thank you so much ! Debbie Ebeley

    Reply
    • ann

      Debra,
      Thank you for reaching out and I totally understand your desire to stick around!
      We actually did not develop the technology in the video; we research new and upcoming innovations with the desire to do exactly as you are asking – getting innovations and therapies to clinical trials and to patients. Right now, the two companies that we shared, that look like interesting potential treatments for TNBC, are not yet in clinical trials. That is the reason that Cancer Fund exists – to get the funds these innovators need, to be able to move their innovations forward and to get to patients, like us, as quickly as possible.

      Having said that about Cancer Fund – has anyone given you a resource so you can look up clinical trials yourself? If not, be sure to go to http://www.clinicaltrials.gov. Currently, with just a quick glance, there are 23 clinical trials of TNBC. Some have completed, some are in progress and some are recruiting, so I hope you can find something you might qualify for.

      I hope this helps and if you would like to connect with me personally, please do not hesitate to email me – ann@cancerfund.com.

      Best of luck! 🍀
      ~ Ann

      Reply

Submit a Comment

Your email address will not be published. Required fields are marked *